异基因造血干细胞移植后诊断为慢性淋巴细胞白血病患者的预后:来自三级保健中心的结果。

Q1 Medicine

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2023-04-04 DOI:10.1016/j.hemonc.2021.09.008

Swe Mar Linn, Ram Vasudevan Nampoothiri, Carol Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Arjun Datt Law, Fotios V Michelis, Dennis D H Kim, Armin Gerbitz, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya

{"title":"异基因造血干细胞移植后诊断为慢性淋巴细胞白血病患者的预后:来自三级保健中心的结果。","authors":"Swe Mar Linn, Ram Vasudevan Nampoothiri, Carol Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Arjun Datt Law, Fotios V Michelis, Dennis D H Kim, Armin Gerbitz, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya","doi":"10.1016/j.hemonc.2021.09.008","DOIUrl":null,"url":null,"abstract":"Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is currently the only curative treatment for patients with chronic lymphocytic leukemia (CLL).Methods: We analyzed the outcomes of 93 patients (median age: 52 years) who underwent allo-HCT at our center between 1989 and 2019.Results: After a median follow-up of 35 months, relapse was observed in 15.1% (n = 14) patients. The estimated 2-year non-relapse mortality, relapse-free survival, and overall survival (OS) were 38.1%, 54.2%, and 58.7%, respectively. The ECOG performance status ≥ 2 (hazard ratio [HR]: 4.1; p = .001) and use of total body irradiation (in a myeloablative conditioning regimen; HR: 2.64; p = .005) were predictive of poor OS after multivariable analysis. The occurrence of sinusoidal obstruction syndrome/veno-occlusive disease post-transplant was associated with poor survival (p = .001).Conclusion: Although the use of kinase and bcl2 inhibitors may result in a decrease in the number and need of transplants, allo-HCT remains a viable option in selected patients with high-risk CLL and good performance status.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"16 3","pages":"230-237"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcomes of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Tertiary Care Center.\",\"authors\":\"Swe Mar Linn, Ram Vasudevan Nampoothiri, Carol Chen, Ivan Pasic, Zeyad Al-Shaibani, Wilson Lam, Arjun Datt Law, Fotios V Michelis, Dennis D H Kim, Armin Gerbitz, Jeffrey Lipton, Rajat Kumar, Jonas Mattsson, Auro Viswabandya\",\"doi\":\"10.1016/j.hemonc.2021.09.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is currently the only curative treatment for patients with chronic lymphocytic leukemia (CLL).Methods: We analyzed the outcomes of 93 patients (median age: 52 years) who underwent allo-HCT at our center between 1989 and 2019.Results: After a median follow-up of 35 months, relapse was observed in 15.1% (n = 14) patients. The estimated 2-year non-relapse mortality, relapse-free survival, and overall survival (OS) were 38.1%, 54.2%, and 58.7%, respectively. The ECOG performance status ≥ 2 (hazard ratio [HR]: 4.1; p = .001) and use of total body irradiation (in a myeloablative conditioning regimen; HR: 2.64; p = .005) were predictive of poor OS after multivariable analysis. The occurrence of sinusoidal obstruction syndrome/veno-occlusive disease post-transplant was associated with poor survival (p = .001).Conclusion: Although the use of kinase and bcl2 inhibitors may result in a decrease in the number and need of transplants, allo-HCT remains a viable option in selected patients with high-risk CLL and good performance status.\",\"PeriodicalId\":39226,\"journal\":{\"name\":\"Hematology/ Oncology and Stem Cell Therapy\",\"volume\":\"16 3\",\"pages\":\"230-237\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology/ Oncology and Stem Cell Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.hemonc.2021.09.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/ Oncology and Stem Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.hemonc.2021.09.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

背景:同种异体造血干细胞移植是目前治疗慢性淋巴细胞白血病(CLL)的唯一方法。方法:我们分析了1989年至2019年期间在我们中心接受了alloo - hct的93例患者(中位年龄:52岁)的结果。结果:中位随访35个月后，15.1% (n = 14)患者复发。估计2年非复发死亡率、无复发生存率和总生存率(OS)分别为38.1%、54.2%和58.7%。ECOG性能状态≥2(风险比[HR]: 4.1;P = .001)和使用全身照射(在清髓调理方案中;人力资源:2.64;p = .005)，多变量分析后预测OS较差。移植后窦阻塞综合征/静脉闭塞疾病的发生与较差的生存率相关(p = 0.001)。结论:尽管使用激酶和bcl2抑制剂可能会导致移植数量和需求的减少，但对于选择的高风险CLL患者和良好的表现状态，allo-HCT仍然是一种可行的选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Outcomes of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Tertiary Care Center.

Background: Allogeneic hematopoietic stem cell transplantation (allo-HCT) is currently the only curative treatment for patients with chronic lymphocytic leukemia (CLL).

Methods: We analyzed the outcomes of 93 patients (median age: 52 years) who underwent allo-HCT at our center between 1989 and 2019.

Results: After a median follow-up of 35 months, relapse was observed in 15.1% (n = 14) patients. The estimated 2-year non-relapse mortality, relapse-free survival, and overall survival (OS) were 38.1%, 54.2%, and 58.7%, respectively. The ECOG performance status ≥ 2 (hazard ratio [HR]: 4.1; p = .001) and use of total body irradiation (in a myeloablative conditioning regimen; HR: 2.64; p = .005) were predictive of poor OS after multivariable analysis. The occurrence of sinusoidal obstruction syndrome/veno-occlusive disease post-transplant was associated with poor survival (p = .001).

Conclusion: Although the use of kinase and bcl2 inhibitors may result in a decrease in the number and need of transplants, allo-HCT remains a viable option in selected patients with high-risk CLL and good performance status.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematology/ Oncology and Stem Cell Therapy Medicine-Hematology

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

27 weeks

期刊介绍： Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.